Heartflow Inc (HTFL) - Market Cap to Earnings

Symbol and logo of brand HeartFlow Medical (HTFL)

HeartFlow Inc (HTFL) provides cloud-based AI vascular diagnostics to meet global demand, which drives the company's P/E ratio dynamics. The -40.90 level captures fresh values as patent protection and FDA approval strengthen the business's position. Growth in the B2B segment relies on the expansion of insurance coverage, rendering the asset independent of economic cycles. This chart allows for an assessment of the balance between market expectations and the corporation's actual profits.

HeartFlow, Inc. (HTFL): Price to Earnings Ratio from 08/09/2025 to 11/10/2026

Comprehensive metric breakdowns and analytics for Heartflow Inc (HTFL)

- share price and expert price forecast:
Price Performance Chart HeartFlow Corp|HTFL - Analyst Consensus Forecast
- market capitalization indicators:
Market Value HeartFlow, Inc.|HTFL - Enterprise Value
- book value of equity indicators:
Book Value per Share HeartFlow|HTFL - Company Book Value|Market Value to Book Value heartflow.com|HTFL - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Heartflow Inc|HTFL - Long-Term Debt to Capital|Current Liabilities to Equity heartflow.com|HTFL - Company Debts|Debt to Book Capitalization Ratio HeartFlow, Inc.|HTFL - Company Long-Term Debt|Short-Term Debt HeartFlow|Quick Liquidity Indicator heartflow.com
- net income and valuation ratios data:
HTFL - Net Income|Expected Net Income Heartflow Inc|HTFL - P/E Multiple|Market Cap to Projected Earnings HeartFlow Inc|HTFL - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation HeartFlow, Inc.|HTFL - Operating profit EBITDA|Net earnings per share for the last 12 months HeartFlow|HTFL - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months heartflow.com|HTFL - Net earnings per share growth this year|Projected earnings per share increase next year Heartflow Inc
Comprehensive company analysis:HeartFlow, Inc.
Finished products of HeartFlow Corp

Fundamental asset screening begins with an analysis of the price-to-earnings ratio, which determines the extent of the asset's overvaluation. The price-to-earnings ratio trend reflects the investment payback period, while for Heartflow Inc (HTFL), a high valuation is justified by unique blood flow analysis algorithms and regulatory barriers that limit the expansion of new diagnostic competitors.

Analysis of competing companies

REGN: Company Value to Net Income|P/E Multiple IRTC|LNTH - Market Cap to Earnings|P/E Multiple MLYS (Mineralys Therapeutics Inc)|P/E Multiple Kestra Medical Corp KMTS|ESPR - Price to Earnings Ratio|Company Value to Net Income AMRN (amarincorp.com)|AVR (anteristech.com) - Price to Earnings Ratio|TNYA: Market Price to Net Income Ratio|CVRX (CVRx, Inc) - P/E Multiple|Milestone Pharmaceuticals Inc - Market Cap to Net Income|Price to Earnings Ratio Cardiol Therapeutics (CRDL)|Price to Earnings Ratio BEAT (heartbeam.com)|Price to Earnings Ratio Tenax Therapeutics, Inc. TENX|Adagio Medical Holdings, Inc. (ADGM) - Market Cap to Earnings|BCDA: Price to Earnings Ratio|Catheter Precision Corporation (VTAK) - Price to Earnings Ratio|ABIO (arcabio.com) - Price to Earnings Ratio|Acasti Pharma Inc. - Company Value to Net Income|AVTE (Aerovate Therapeutics, Inc.) - P/E Multiple|Verve (VERV) - Business Payback Period|Price to Earnings Ratio Windtree Therapeutics (WINT)